2024-519418-29-00Authorised3 期
NBI-1065845-MDD3024: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)
Neurocrine Biosciences Inc.0 个研究点目标入组 24 人开始时间: 2025年6月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- Authorised
- 发起方
- 入组人数
- 24
- 主要终点
- The primary endpoint for this study will be the change from baseline in total MADRS score at Day 56.
研究概览
简要总结
The primary objective for this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in subjects with MDD on improving symptoms of depression, as measured by the Montgomery-Asberg Depression Rating Scale (MADRS).
入排标准
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
The primary endpoint for this study will be the change from baseline in total MADRS score at Day 56.
次要结局
- Change from baseline in SDS total score at Day 56
- Change from baseline in CGI-S score at Day 56
研究者
Neurocrine Medical Information Call Center
Scientific
Neurocrine Biosciences Inc.
相似试验
已完成
2 期
Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)Major Depressive DisorderNCT05203341Neurocrine Biosciences183
招募中
3 期
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Major Depressive DisorderNCT06786624Neurocrine Biosciences200
招募中
3 期
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Major Depressive DisorderNCT06963021Neurocrine Biosciences200
招募中
3 期
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Major Depressive DisorderNCT06911112Neurocrine Biosciences200
招募中
3 期
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaSchizophreniaNCT06963034Neurocrine Biosciences284